Stoke Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	192.01	114.13	145.46	287.51	222.68	105.6	1.85
Short-Term Investments	9.95	116.04	74.92	0	0	0	0
Cash & Cash Equivalents	201.96	230.16	220.38	287.51	222.68	105.6	1.85
Cash Growth	-12.25%	4.44%	-23.35%	29.12%	110.86%	5599.03%	-
Other Current Assets	13.38	13.91	8.84	6.42	3.36	0.54	0.06
Total Current Assets	215.34	244.07	229.22	293.93	226.03	106.14	1.91
Property, Plant & Equipment	12.43	11.43	9.08	3.79	2.51	1.19	0.47
Other Long-Term Assets	0.57	0.57	0.57	0.21	0.21	0.2	0.06
Total Long-Term Assets	13	12	9.65	4	2.72	1.4	0.53
Total Assets	228.34	256.07	238.87	297.93	228.75	107.54	2.44
Accounts Payable	1.7	0.77	2.39	1.5	0.75	1.07	0.14
Deferred Revenue	48.38	51.74	0	0	0	0	0
Other Current Liabilities	-19.26	-21.11	14.75	9.93	3.35	1.4	3.57
Total Current Liabilities	30.82	31.39	17.14	11.43	4.1	2.47	3.72
Other Long-Term Liabilities	37.96	39.82	3.95	0.42	0.22	0	0.02
Total Long-Term Liabilities	37.96	39.82	3.95	0.42	0.22	0	0.02
Total Liabilities	68.78	71.22	21.09	11.85	4.32	2.47	3.73
Retained Earnings	-401.85	-297.15	-196.08	-110.28	-58.04	-25.71	-13.19
Comprehensive Income	-0.02	-1.18	-0.17	0	0	0	0
Shareholders' Equity	159.57	184.85	217.78	286.08	224.43	105.07	-1.29
Net Cash / Debt	201.96	230.16	220.38	287.51	222.68	105.6	1.85
Net Cash / Debt Growth	-12.25%	4.44%	-23.35%	29.12%	110.86%	5599.03%	-
Net Cash Per Share	4.59	5.92	6.00	8.59	12.39	148.88	2.77
Working Capital	184.52	212.68	212.08	282.51	221.93	103.68	-1.81
Book Value Per Share	3.63	4.75	5.93	8.54	12.49	148.12	-1.93

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).